Navigation Links
Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
Date:6/1/2009

fety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborators, including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or conduct of further development and commercialization activities relating to our product candidates. These factors and others are more fully discussed in Micromet's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2009, filed with the SEC on May 11, 2009, as well as other filings by the company with the SEC.


'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
2. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
3. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
4. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
5. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
6. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
7. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
8. Micromet to Present at the Cowen Health Care Conference on March 17, 2009
9. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
10. Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009
11. Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering Pharma AG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 15, 2014 -- According to the International Atomic ... security comes from terrorists acquiring sufficient quantities of ... a crude nuclear explosive device. The IAEA also ... have involved gram-level quantities, which can be challenging ... to a new study appearing this week in ...
(Date:7/10/2014)... basis of psychiatric disorders has been extremely challenging because ... but are insufficient to cause disease. Now investigators reporting ... journal Cell Stem Cell describe a strategy ... interact with other risk factors or environmental exposures to ... pinpoints a genetic variant that may predispose individuals to ...
(Date:7/10/2014)... shelled out for crude 3-D glasses, polarized glasses, ... These basic devices, used to trick the brain ... be rendered obsolete with the introduction of new ... , TAU doctoral students Yuval Yifat, Michal Eitan, ... based on nanoantennas that could be used for ...
(Date:1/15/2014)... "The interface is the device," Nobel laureate Herbert ... to be found at the junctures where layers ... of nanotechnology, the interfaces between layers of metal ... such high-tech favorites as spintronics, high-temperature superconductors, ferroelectrics ...
Breaking Biology Technology:Sensitive detection method may help impede illicit nuclear trafficking 2New strategy could uncover genes at the root of psychiatric illnesses 2Projecting a 3-dimensional future 2Projecting a 3-dimensional future 3A deeper look at interfaces 2
... ANGELES, Feb. 18 The Board of Directors wishes to ... 2009 it resolved to file a Form 15 with effect ... the approval of stockholders but in the interests of keeping ... Release.The effect of this filing is to release the company ...
... SAN DIEGO, Feb. 18 Zogenix, Inc. ("Zogenix"), a ... Drug,Administration (FDA) has provided a target date of July ... for Sumavel DosePro (sumatriptan,injection) needle-free delivery system. Zogenix ... treatment of migraine attacks with or without,aura, and the ...
... Inc. (the "Company") (Nasdaq: PDGI ), a ... biotechnology, generic drug and medical device companies, today announced ... Brazil to further enhance its Latin American presence.PharmaNet has ... 2002 with a network of field-based staff in Brazil, ...
Cached Biology Technology:EESTECH Inc - Release From SEC Filing 2EESTECH Inc - Release From SEC Filing 3EESTECH Inc - Release From SEC Filing 4Zogenix Reports FDA Provides New PDUFA Date for Sumavel(TM) DosePro(TM) 2PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office 2PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office 3PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office 4PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office 5
(Date:7/11/2014)... There is evidence that under the normal ... and development, maintain neuronal environment, and exhibit ... and neurodegenerative disease. Previous studies have found ... cells after chemical induction have reduced viability, ... application. Prof. Xiaodong Yuan, Kailuan General Hospital, ...
(Date:7/11/2014)... Research and Markets has announced the addition ... Analysis Size Share Growth Trends and Forecast to 2019" ... http://photos.prnewswire.com/prnh/20130307/600769 The rising number of ... high level security in both private and public sector. ... and passwords, tokens etc. are vulnerable to attacks. Biometrics ...
(Date:7/11/2014)... of all vertebrates, information is transmitted through synapses, ... signal to be passed from one brain cell ... abundant type of synapse, can be either excitatory ... memory, perception and cognition, and the balance between ... For instance, every time we learn something, ...
Breaking Biology News(10 mins):International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2Blame it on the astrocytes 2
... HILO, HawaiiIn collaboration with Stanford University and ... Service Pacific Southwest Research Station,s Institute of Pacific ... developing "hybrid ecosystems"a mix of native and non-native ... in tropical forests. The research team, comprised ...
... parrots and iguanas may seem inoffensive at first glance when ... escape and become invasive species. This has been confirmed by ... 63 Spanish zoos. Birds are the animals most likely to ... (non-indigenous) species, they could become an entry channel for these ...
... -- Specialized white blood cells called T cells and ... and eliminate "non-self" substances such as viruses and bacteria. ... immunoreceptors on the cell surface bind to specific regions on, ... pathways inside the T cells and B cells that control ...
Cached Biology News:US Forest Service and 2 universities team up to develop new ecosystems for Hawaiian forests 275 percent of Spanish zoos at risk of exotic animals escaping 275 percent of Spanish zoos at risk of exotic animals escaping 3
Recombinant Equine IL-6...
... two highly efficient methods of identifying recombinant ... By using the large-scale screen method in ... is to transfer partial colonies of E. ... into the solutions provided by the kits ...
... Fernandez and G. Butcher (1998). • The ... much research in the immunology area. There ... MHC proteins and in their function as ... faced with the prospect of tackling biochemical ...
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
Biology Products: